Close

Aimmune Therapeutics (AIMT) Announces Presentation of AR101 Phase 2, Biomarker Data at FARE Retreat

April 11, 2016 7:08 AM EDT Send to a Friend
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODITâ„¢ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login